Stockscreener 앱 받기
4.98
1.43%
0.07
Insight Molecular Diagnostics Inc 주식(IMDX)의 최신 뉴스
Insight Molecular Diagnostics Inc. Q1 earnings preview - MSN
IMDX SEC FilingsInsight Molecular Diagnostics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Insight Molecular Diagnostics Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
MSN Money - msn.com
Number of shareholders of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX - TradingView
Insight Molecular Diagnostics Inc. (IMDX) - Zacks Investment Research
Alpha Buying: Insider Conviction in High-Risk Biotech - Sahm
iMDx will post quarterly results May 13, then take investor questions live - Stock Titan
iMDx to Release First Quarter 2026 Results on May 13, 2026 - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: GeneDx Holdings (WGS), Pfizer (PFE) and Travere Therapeutics (TVTX) - The Globe and Mail
Insight Molecular Corrects Bylaws Disclosure in Annual Report - TipRanks
IMDX (NASDAQ: IMDX) outlines 2026 proxy votes, FDA dd-cfDNA strategy - Stock Titan
[8-K] Insight Molecular Diagnostics Inc. Reports Material Event - Stock Titan
How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With Funding And GraftAssureDx Milestones - Yahoo Finance
Broadwood Partners, Neal C. Bradsher buy $2.03m of Insight Molecular Diagnostics - Investing.com India
Broadwood and Neal Bradsher hold 39.7% of Insight Molecular (IMDX) shares - Stock Titan
Broadwood entities add 570K IMDX shares, hold 12.7M plus warrants - Stock Titan
Insight Molecular Diagnostics Inc. Q4 2025 earnings preview - MSN
Insight Molecular Diagnostics prices $26M registered direct offering; shares down - MSN
Major Investor Makes Bold Move Into Insight Molecular Diagnostics - TipRanks
Broadwood Partners buys $652,875 in Insight Molecular Diagnostics By Investing.com - Investing.com South Africa
Broadwood Partners buys $652,875 in Insight Molecular Diagnostics - Investing.com
Broadwood boosts Insight Molecular (IMDX) stake with 182,861-share buy - Stock Titan
Insight (IMDX) Stock Range-Bound (Marginal Loss) 2026-04-20Gap Down Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Needham Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛
Stock List: Research Stocks from Around the World - GuruFocus
IMDX: GraftAssure's decentralized PCR test drives transplant diagnostics innovation and market expansion - TradingView
IMDX: GraftAssure aims to transform transplant diagnostics with decentralized, high-margin testing - TradingView — Track All Markets
Real-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure Assay - marketscreener.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Kidney transplant test data heads to 3 global medical meetings - Stock Titan
Real-World Evidence and Industry Momentum Builds for iMDx’s Flagship GraftAssure Assay - GlobeNewswire
Why The Insight Molecular Diagnostics (IMDX) Story Is Shifting After Cash Raise And FDA Catalyst - Yahoo Finance
IMDX Options Volatility — NASDAQ:IMDX - TradingView
IMDX Options Chain — NASDAQ:IMDX - TradingView
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Capital expenditures of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX - TradingView
IMDX Technical Analysis & Stock Price Forecast - Intellectia AI
Insight Molecular Diagnostics Inc. Stock Forecast Summary - Meyka
IMDX Submits Kitted Transplant Rejection Test for FDA Review - Clinical Lab Products
BTIG reiterates Neutral rating on Insight Molecular stock By Investing.com - Investing.com Canada
BTIG reiterates Neutral rating on Insight Molecular stock - Investing.com
Insight Molecular (IMDX) Soars 22.36% During Intraday Rally — What’s Driving the Market Turbulence? - Bitget
0.89%
0.56%
자본화:
|
볼륨(24시간):